Abstract
Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review for 60 patients who received ceftazidime-avibactam for a CRE infection. In-hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.
Keywords:
antibiotic resistance; beta-lactamases; carbapenemase.
Copyright © 2017 American Society for Microbiology.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Azabicyclo Compounds / therapeutic use*
-
Carbapenem-Resistant Enterobacteriaceae / drug effects
-
Carbapenem-Resistant Enterobacteriaceae / pathogenicity
-
Carbapenems / therapeutic use
-
Ceftazidime / therapeutic use*
-
Cephalosporins / therapeutic use
-
Drug Combinations
-
Drug Resistance, Multiple, Bacterial
-
Enterobacteriaceae / drug effects
-
Enterobacteriaceae / pathogenicity
-
Enterobacteriaceae Infections / drug therapy
-
Hospital Mortality
-
Humans
-
Microbial Sensitivity Tests
-
Retrospective Studies
-
beta-Lactamase Inhibitors / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Carbapenems
-
Cephalosporins
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
beta-Lactamase Inhibitors
-
Ceftazidime